A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
about
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsAnastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsAssessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Multiple gene aberrations and breast cancer: lessons from super-responders.PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.Challenges and perspective of drug repurposing strategies in early phase clinical trials.Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapyPotential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsA Review of mTOR Pathway Inhibitors in Gynecologic CancerSmall-molecule inhibitors of the HIF pathway and synthetic lethal interactions.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Targeting PI3K in Cancer: Any Good News?PI3K/AKT signaling pathway and cancer: an updated review.Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I.Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.
P2860
Q27853151-C85C4041-233C-4253-810F-5E11372FC988Q30411680-312F2E19-7DA9-437D-8814-6ECE0B8CAF9AQ31060162-7E1D9CD0-F9AD-493D-BA3D-E1963535F790Q33414685-7D39CEB4-0199-4ADF-922B-5930896FF508Q33756991-258C62B0-64F8-41A9-9861-498774B343ADQ33917551-E5102D7B-628F-43FD-B10C-B263D441699FQ34153696-4C678959-8EA4-43B4-951B-4D1FFF7B4E3BQ34646376-640E5DF6-D24A-48CD-8140-D8217FEDE4BBQ35535953-7578E0D8-46B7-4109-96AE-0F77D73DAF20Q35645466-BEF9956F-B7F1-490A-ADDF-F3CFD00CB884Q35808438-EB9B22A0-6F44-4986-A120-007A9DDCEDD2Q35863063-B646061D-4EA2-4D69-BB2E-131AAE538556Q36173653-83CDBE83-21DD-4336-838E-D706E2881721Q36206239-15B8D776-B272-4535-96EE-8D166BFA9AD2Q36510935-129476AF-7A7D-43A9-BC5E-66AA9E549E1BQ37668889-8811B8D3-D81A-45DE-B909-C3BC86A21A6BQ38003390-67AC372E-B0DE-4802-B629-C733BB0C2A5CQ38042638-EB281573-1FFB-4777-B07B-8005692439C1Q38105322-B0A80310-9DAC-42D3-ADC2-10D0E3B64A8DQ38217651-84EEAE65-9685-40F3-B384-E12F5E3B74ACQ38258712-198B0471-7A75-4A18-A86E-8B3AD2966242Q38371672-821E7A6B-06D5-45D6-BD00-832D06554A36Q39000880-922F8EA8-8402-4FF2-8ADC-A03227F062C4Q39748979-72381D4A-CC07-4E94-956E-1689E43E9B7BQ50101328-5E6D63D6-D751-46C3-98B5-C828647BF2B7
P2860
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase I trial of liposomal d ...... logic and breast malignancies.
@ast
A phase I trial of liposomal d ...... logic and breast malignancies.
@en
type
label
A phase I trial of liposomal d ...... logic and breast malignancies.
@ast
A phase I trial of liposomal d ...... logic and breast malignancies.
@en
prefLabel
A phase I trial of liposomal d ...... logic and breast malignancies.
@ast
A phase I trial of liposomal d ...... logic and breast malignancies.
@en
P2093
P2860
P50
P1476
A phase I trial of liposomal d ...... logic and breast malignancies.
@en
P2093
David S Hong
John W Moroney
Matthew P Schlumbrecht
Robert L Coleman
Stacy Moulder
Thorunn Helgason
P2860
P304
P356
10.1158/1078-0432.CCR-11-0666
P407
P577
2011-09-02T00:00:00Z